Merck and Moderna say their individualized mRNA cancer vaccine met its endpoints in a Phase 3 melanoma trial, and Moderna’s stock closed up 177 percent. What the therapy is, why decades of cancer vaccines failed before it, and Japanese reactions on X to the news.